Erschienen in:
01.04.2016
Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis
verfasst von:
Susan E. Yount, Jennifer L. Beaumont, Shih-Yin Chen, Karen Kaiser, Katy Wortman, David L. Van Brunt, Jeffrey Swigris, David Cella
Erschienen in:
Lung
|
Ausgabe 2/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Idiopathic pulmonary fibrosis (IPF) produces symptoms and activity limitations that impair health-related quality of life (HRQOL). The Patient-Reported Outcomes Measurement Information System® (PROMIS®) includes measures of self-reported health and HRQOL for a range of conditions. This study evaluated the HRQOL of individuals with IPF using PROMIS measures and examined associations between HRQOL and key symptoms or supplemental oxygen need.
Methods
Individuals who reported being told by a doctor that they have IPF completed an online battery of measures at baseline and 7–10 days later (for test–retest reliability). Measures included a brief survey of demographic and health-related questions, the PROMIS-29 profile, the Modified Medical Research Council Dyspnea Scale (MMRC), PROMIS dyspnea severity short form, A Tool to Assess Quality of life in IPF (ATAQ-IPF) and one cough item from the Functional Assessment of Chronic Illness Therapy (FACIT).
Results
220 individuals were included in the final sample. Except for sleep disturbance, all PROMIS domain scores significantly (p < .01) differed by MMRC level. Supplemental oxygen users were more impaired than non-users in fatigue, physical function, and social role participation (p < 0.01). The test–retest reliability was acceptable to excellent (>0.7) for all scales, but was lower for sleep disturbance (0.64).
Conclusions
People with IPF report substantial deficits in HRQOL across a range of PROMIS domains, and deficits vary by dyspnea and cough severity. These deficits warrant monitoring in clinical practice and consideration when investigating new therapies. Further research is required to further evaluate the psychometric performance of the PROMIS-29 in IPF.